Suggestions
Andy Scharenberg
Chief Executive Officer at Umoja Biopharma
Professional Background
Andy Scharenberg is a highly accomplished medical professional and esteemed leader in the biopharmaceutical industry, currently serving as the Chief Executive Officer at Umoja Biopharma. With an extensive background that spans academia and the biotech sector, Andy has dedicated his career to advancing therapeutic interventions aimed at tackling some of the most challenging health issues.
Previously, he has held significant positions including co-founder and Chair of the Scientific Advisory Board at Generation Bio, a pioneering organization focused on developing gene therapies, where he contributed to shaping innovative solutions in the realm of genetic medicine. Andy's commitment to medical science is evident through his role as the Chair of the Scientific Advisory Board at Alpine Immune Sciences, where he directed focus on immune-mediated therapies.
A prominent figure in research and clinical settings, Andy served as a Professor of Pediatrics and Immunology at the University of Washington, contributing to both education and research in pediatric care and immunological advancements. His tenure as Principal Investigator at Seattle Children's Hospital and Research Institute showcased his dedication to translating scientific discoveries into tangible health benefits for children.
In the corporate world, Andy excelled as the Chief Scientific Officer at Casebia Therapeutics, where he was instrumental in guiding cutting-edge research initiatives aimed at tackling genetic diseases. His previous experience also includes serving on the Scientific Advisory Board at bluebird bio and holding the role of Chief Scientific Officer at Cellectis therapeutics, contributing to the pioneering field of gene editing and cellular therapies. Additionally, he was a co-founder and member of the Board of Directors at Pregenen, further highlighting his entrepreneurial spirit and commitment to fostering innovation in healthcare.
Education and Achievements
Andy Scharenberg earned his MD in Medicine from the prestigious University of North Carolina School of Medicine, a foundation that has enabled him to steer innovative scientific research and development in the medical field. His educational background in medicine underpins his vast expertise in immunology and pediatric care, informing his decisions and strategies as both a leader in scientific research as well as in executive roles at various biopharmaceutical firms.
His leadership experience and comprehensive understanding of the biomedical landscape uniquely position him to champion initiatives that bridge the gap between scientific discovery and clinical applications. Throughout his career, Andy has strived to enhance patient care through translational science, making significant contributions to the legacy of human health advancement.
Achievements
Throughout his illustrious career, Andy Scharenberg has amassed a plethora of achievements, impacting both the scientific community and patient care. His role in advancing genetic and immunological therapies through executive and advisory positions has set benchmarks within the biotechnology industry. His leadership at Umoja Biopharma is a testament to his forward-thinking vision and commitment to harnessing science in the service of humanity.
By laying the groundwork for novel therapeutic approaches in institutions he has led, Andy has influenced many successful collaborations, innovative product developments, and research breakthroughs.
In summary, Andy Scharenberg's impressive educational background in medicine, extensive experience in various high-impact roles within the biopharmaceutical sector, and unwavering dedication to scientific research and innovation have made him a key figure in advancing healthcare solutions. His vision for the future of medicine inspires others and demonstrates a clear commitment to enhancing the quality of life and health outcomes for patients worldwide.
